This event has ended

MaRS Future of Medicine™ - Assessing Breast Cancer Risk

MaRS Discovery District

Monday, May 14, 2012 from 12:00 PM to 1:00 PM (EDT)

Toronto, Canada

MaRS Future of Medicine™ - Assessing Breast Cancer Risk

Ticket Information

Type End     Quantity
General Attendance Ended Free  

Share MaRS Future of Medicine™ - Assessing Breast Cancer Risk

Event Details

Joel will review the current techniques for breast cancer risk management, the limitations of these techniques, and the opportunities for substantial improvement in cost-effectiveness, access and outcomes. In this context, Joel will review the regulatory and clinical burdens that need to be overcome to bring novel risk management tools to market, and will use SenoSENSE Medical Systems as a case study for how this can be done efficiently.

MaRS Future of Medicine™ Series is a must-attend event for anyone engaged in translational research or commercial development within the life sciences.

Part of the MaRS Future of Medicine™ Series


About the Speaker

Joel Ironstone is founder and CEO of SenoSENSE Medical Systems. He has more than 10 years of experience leading the design and development of complex and novel medical systems both in startup ventures and established companies. Joel has worked in leadership roles in operations, software and hardware development, clinical study design, project management, manufacturing and regulatory affairs. His career spans both diagnostic and therapeutic product areas in women’s health, neurology and critical care. Joel is a named inventor on over a dozen patents, and is a co-author on several peer-reviewed scientific publications and presentations in neuroscience, biomedical engineering and radiology.

About SenoSENSE

SenoSENSE Medical Systems is a Toronto-based company committed to significantly reducing the impact of breast cancer in women. Breast cancer is the leading cause of death in women 30-50 years old — an age group of women who are not currently screened. SenoSENSE’s leading product, the Electronic Breast Densitometer, measures breast density, which is the most important risk factor for breast cancer. The device can be deployed at a primary care physician’s office to identify high-risk women among those who are not currently being screened, so they can engage in earlier surveillance or take other steps to significantly reduce their risk.



Have questions about MaRS Future of Medicine™ - Assessing Breast Cancer Risk? Contact MaRS Discovery District

When & Where

101 College Street
Toronto, M5G 1L7

Monday, May 14, 2012 from 12:00 PM to 1:00 PM (EDT)

  Add to my calendar


MaRS Discovery District

MaRS ( is a large scale, mission driven innovation centre located in Toronto and networked across Ontario, focused on building Canada’s next generation of technology companies.

MaRS works closely with entrepreneurs to grow and scale their ventures into global market leaders in life sciences and health care, information, communications and entertainment technologies, cleantech, advanced materials and engineering, as well as innovative social purpose businesses.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.